Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

2.2K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.2K
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

1.7K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
1.7K
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

44
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
44
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

801
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
801
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

813
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
813
Chemical Synapses01:26

Chemical Synapses

9.2K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
9.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying Subclinical Transthyretin Cardiac Amyloidosis in V142I TTR Carriers: Design, Rationale, and Methods of the VISTA (Variant Imaging of Subclinical Transthyretin Amyloidosis) Study.

The American journal of cardiology·2026
Same author

Key Findings From the World Federation of Haemophilia National Member Organization Survey on Women and Girls With Bleeding Disorders.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Shared burden of ultra-rare genetic variants across a spectrum of motor neuron diseases.

Translational neurodegeneration·2025
Same author

A Rare Unusually Aggressive Form of Hereditary Transthyretin Amyloidosis.

JACC. Case reports·2025
Same author

Confirmatory long-term efficacy and safety results of ataluren in patients with nmDMD from Study 041, an international, randomized, double-blind, placebo-controlled, Phase III trial.

Journal of comparative effectiveness research·2025
Same author

Patient and Family Engagement in Australian and New Zealand Adult Critical Care Trials.

Annals of the American Thoracic Society·2025
Same journal

Sports Neurology.

Neurologic clinics·2026
Same journal

Sports-Related Peripheral Nerve Injuries.

Neurologic clinics·2026
Same journal

Active Rehabilitation and Return to Play in Sports-Related Concussion.

Neurologic clinics·2026
Same journal

Autonomic Assessment and Management in Sports-Related Concussion.

Neurologic clinics·2026
Same journal

Management of Vestibular Symptoms in Sports-Related Concussion.

Neurologic clinics·2026
Same journal

Neuropsychological Assessment in Sport-Related Concussion: Evidence, Controversies, and Clinical Applications.

Neurologic clinics·2026
See all related articles

Related Experiment Video

Updated: Apr 26, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.3K

Muscle channelopathies.

Jeffrey Statland1, Lauren Phillips2, Jaya R Trivedi2

  • 1Department of Neurology, University of Rochester, 601 Elmwood Drive, Rochester, NY 14607, USA.

Neurologic Clinics
|July 20, 2014
PubMed
Summary
This summary is machine-generated.

Skeletal muscle channelopathies, like congenital myasthenic syndrome, present diverse symptoms challenging diagnosis and treatment. Early symptom recognition and management can improve patient quality of life.

Keywords:
ChannelopathiesCongenital myasthenic syndromeIon channelNondystrophic myotoniaPeriodic paralysis

More Related Videos

Functional Characterization of Endogenously Expressed Human RYR1 Variants
07:59

Functional Characterization of Endogenously Expressed Human RYR1 Variants

Published on: June 9, 2021

2.3K
Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

14.9K

Related Experiment Videos

Last Updated: Apr 26, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.3K
Functional Characterization of Endogenously Expressed Human RYR1 Variants
07:59

Functional Characterization of Endogenously Expressed Human RYR1 Variants

Published on: June 9, 2021

2.3K
Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

14.9K

Area of Science:

  • Neurology
  • Genetics
  • Molecular Biology

Background:

  • Skeletal muscle channelopathies are rare, heterogeneous disorders.
  • They exhibit significant genotypic and phenotypic variability.
  • Diverse manifestations pose diagnostic and therapeutic challenges, impacting quality of life.

Purpose of the Study:

  • To summarize clinical features, diagnostic approaches, pathophysiology, and treatment strategies.
  • To cover nondystrophic myotonia, congenital myasthenic syndrome, and periodic paralyses.
  • To inform clinicians on managing these rare neuromuscular conditions.

Main Methods:

  • Literature review and synthesis of current knowledge.
  • Focus on clinical manifestations and diagnostic studies.
  • Examination of pathophysiology and therapeutic options.

Main Results:

  • Nondystrophic myotonia, congenital myasthenic syndrome, and periodic paralyses share challenges in diagnosis and treatment.
  • Understanding molecular pathology is advancing, but clinical variability persists.
  • No FDA-approved treatments exist; symptom management is key.

Conclusions:

  • Skeletal muscle channelopathies require careful diagnosis and management.
  • Symptomatic treatment can reduce morbidity and enhance quality of life.
  • Further research is needed for targeted therapies.